RA CAPITAL MANAGEMENT, L.P.
Q3 2021 13F-HR Holdings
Net value change ($000)
+986,294
(15.8%)
New positions
21
Sold out positions
17
Turnover %
29.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ASND | 282,183 | 31.5% |
| CLYM | 236,452 | NEW |
| IVVD | 225,567 | NEW |
| CTKB | 205,686 | NEW |
| Icosavax, Inc. | 171,011 | NEW |
| DICE Therapeutics, Inc. | 170,592 | NEW |
| ABOS | 145,194 | NEW |
| TYRA | 127,289 | NEW |
| CLDX | 86,384 | NEW |
| AVIR | 74,980 | 65.0% |
Top Reduces (Value $000, Stocks/ETFs)
| AXSM | -111,676 | -100.0% |
| NVAX | -108,602 | -20.0% |
| CRIS | -57,621 | -100.0% |
| Cerevel Therapeutics Holdings, Inc. | -56,364 | -100.0% |
| Trillium Therapeutics Inc. | -51,318 | -100.0% |
| ARDX | -46,066 | -100.0% |
| ChemoCentryx, Inc. | -43,083 | -92.0% |
| ZOGENIX, INC. | -40,668 | -44.5% |
| LEGN | -40,126 | -100.0% |
| LENZ | -38,695 | -46.7% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|